Impact of a code stroke protocol on the door-to-needle time for IV thrombolysis: a feasibility study

ABSTRACT Introduction Stroke is a development of an acute focal neurological deficit with an ischemic or hemorrhagic origin. Thrombolysis within 4.5 h of ischemic stroke onset improves outcome. Guidelines recommend administration of intravenous recombinant tissue plasminogen activator within 60 min upon arrival at the hospital, meaning the door-to-needle time (DNT) should be less than 60 min. In this study, a stroke protocol was introduced at the emergency department of the Ghent University Hospital with a primary goal to shorten the DNT. Methodology This study was an uncontrolled before-after cohort study. A ‘Code Stroke’ protocol (CSP) was implemented and the results from the pre-code stroke protocol period (Pre-CSP period, from 15 August 2016 until 5 March 2017) were compared with the results from the post-code stroke protocol period (Post-CSP period, from 6 March 2017 until 16 July 2017). Results The median DNT decreased significantly from 57 min in the Pre-CSP period to 33 min in the Post-CSP period (p < 0.001). The door-to-triage time (DTT), triage-to-emergency physician time (TET), emergency physician-to-CT time (ECT) and CT-to needle time (CNT) decreased significantly Post-CSP compared to Pre-CSP. When adjusting the results for other variables that might have an influence on these time intervals, the TET, ECT and CNT also decreased significantly. There was a statistically significant effect of the implementation of the CSP on the number of patients treated with a DNT within 20, 30, 45 and 60 min (p = 0.008). Conclusion A significant decrease in DNT can be achieved with the implementation of this stroke protocol.

[1]  Atte Meretoja,et al.  Reducing in-hospital delay to 20 minutes in stroke thrombolysis , 2012, Neurology.

[2]  R. M. Van den Berg-Vos,et al.  Achieving a door-to-needle time of 25 minutes in thrombolysis for acute ischemic stroke: a quality improvement project. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[3]  D. Pandey,et al.  Epidemiology of ischemic and hemorrhagic stroke: incidence, prevalence, mortality, and risk factors. , 2008, Neurologic clinics.

[4]  L. Goldstein,et al.  BE-FAST (Balance, Eyes, Face, Arm, Speech, Time): Reducing the Proportion of Strokes Missed Using the FAST Mnemonic , 2017, Stroke.

[5]  Eric E. Smith,et al.  Improving Door-to-Needle Times in Acute Ischemic Stroke: The Design and Rationale for the American Heart Association/American Stroke Association's Target Stroke Initiative , 2011, Stroke.

[6]  Gregory W Albers,et al.  Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.

[7]  Adrian F Hernandez,et al.  Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke: Patient Characteristics, Hospital Factors, and Outcomes Associated With Door-to-Needle Times Within 60 Minutes , 2011, Circulation.

[8]  L. Beenen,et al.  Thrombolysis in Stroke within 30 Minutes: Results of the Acute Brain Care Intervention Study , 2016, PloS one.

[9]  J. Willey,et al.  Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous recombinant tissue plasminogen activator: a review of natural history and treatment. , 2014, JAMA neurology.

[10]  Atte Meretoja,et al.  Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months , 2013, Neurology.

[11]  Eric E. Smith,et al.  Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target Stroke , 2017, Circulation. Cardiovascular quality and outcomes.